Descrizione del progetto
Prevenire l’ictus grazie allo smartphone
La fibrillazione atriale (FA) è una condizione patologica che provoca un battito cardiaco irregolare e spesso rapido. Si tratta del tipo più diffuso di aritmia cardiaca sostenuta è può portare all’ictus, motivi per cui diagnosticarla precocemente risulta importante. Ciononostante, i metodi di rilevamento della FA tradizionali quali l’elettrocardiogramma (ECG) e il monitoraggio tramite holter di 24 ore offrono un tasso di successo inferiore al 20 %. Alla luce di tali premesse, il progetto RedStroke, finanziato dall’UE, sta sviluppando una nuova soluzione TIC intelligente per uno screening della FA preciso ed efficiente in termini di costi, con l’obiettivo di prevenire l’ictus sulla base delle tecnologie presenti in uno smartphone convenzionale. In particolare, lo screening della FA verrà effettuato con una precisione comparabile all’ECG, in modo istantaneo e con il solo impiego di uno smartphone.
Obiettivo
Stroke is the second most common cause of death and complex disability, accounting for ~1 million deaths in Europe each year. Total cost of stroke in the EU amounts to €65 billion a year. Main risk factor for stroke is atrial fibrillation (AF), the most common type of sustained cardiac arrhythmia. Early identification of AF can prevent strokes as treatment can be started on time. However, AF is difficult to capture and often not noticed. Classical AF detection methods (electrocardiogram [ECG] and 24 hour-holter-ECG) have less than 20% success rate. Plus these methods are costly and not suitable for routine large-scale screening. German SME company Preventicus developed a smart ICT solution for accurate and cost-efficient AF screening, aiming to prevent stroke, based on technologies present in a standard smartphone. Its technology is clinically proven in international studies (accuracy: 96%, predictive value: >99%). To ensure wide deployment as structured AF detection program, Preventicus has set-up clinical grade services surrounding its ‘core’ technology, e.g. Telecare service to verify AF suspects, to safeguard timely referral of the screened AF-patients to a cardiologist for AF confirmation and treatment initiation. The target market is an attractive high volume market (~150-200M end-users in Europe). Preventicus is the first European player in the market (all its competitors are US-based). As such, investments in the company will enhance Europe’s standing in the smart healthcare technologies market vis à vis the USA. Following successful commercialisation in Germany (~170,000 active users and sales to large health insurance companies), Preventicus is now ready to accelerate growth beyond Germany. Funding will allow the company to take the final steps needed for EU-wide roll-out, directly driving employment growth and profitability of the company (estimated cumulative revenues: €78 million in 2025, representing return of investment of >31 times the EIC grant)
Campo scientifico
- medical and health scienceshealth scienceshealth care serviceseHealth
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- medical and health scienceshealth sciencespublic health
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
- medical and health sciencesbasic medicineneurologystroke
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-2
Meccanismo di finanziamento
SME - SME instrumentCoordinatore
07743 Jena
Germania
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.